5 Most Promising Healthcare Stocks According to Analysts

2. Lantheus Holdings, Inc. (NASDAQ:LNTH)

Number of Hedge Fund Holders: 44

One-Year Average Price Estimate: $108.38

Massachusetts-based diagnostics imaging products company Lantheus Holdings, Inc. (NASDAQ:LNTH) is one of the most promising healthcare stocks to buy according to analysts. Earlier this month, JMP Securities started covering Lantheus Holdings, Inc. (NASDAQ:LNTH) with a Market Perform rating. The firm said that Lantheus Holdings, Inc. (NASDAQ:LNTH) has expanded to become a “MedTech growth leader with sustainability for years to come.” JMP set a whopping $120 price target on Lantheus Holdings, Inc. (NASDAQ:LNTH). This price target is even better than the average price target of $108 on Lantheus Holdings, Inc. (NASDAQ:LNTH), which already presents a strong upside potential from the current levels.

Hedge funds were also piling into Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter of 2022. At the end of the period, 44 hedge funds out of the 943 tracked by Insider Monkey had stakes in Lantheus Holdings, Inc. (NASDAQ:LNTH). This was up from 35 hedge funds in the previous quarter. The most notable hedge fund stakeholder of Lantheus Holdings, Inc. (NASDAQ:LNTH) was Ken Griffin’s Citadel Investment Group which owns a $39 million stake in the company.

Carillon Eagle Small Cap Growth Fund made the following comment about Lantheus Holdings, Inc. (NASDAQ:LNTH) in its Q4 2022 investor letter:

“Lantheus Holdings, Inc. (NASDAQ:LNTH) provides imaging diagnostics, targeted therapeutics, and artificial intelligence solutions used to fight serious medical conditions. Despite another strong quarterly update, the stock came under pressure due in part to investor concerns regarding a possible deceleration of revenue growth in the company’s leading product, Pylarify, as the company seems to have penetrated most of the early adopters of this imaging agent for prostate cancer. Later in the quarter, the company announced a strategic collaboration and exclusive licensing agreement for two late-stage therapeutic products used for the treatment of metastatic prostate cancer and neuroendocrine tumors. We believe approval of these products should help offset any significant declines in revenue growth of Pylarify.”